Fluticasone Furoate (Asthma) – Forecast and Market Analysis to 2023: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on sales@marketoptimizer.org with Fluticasone Furoate (Asthma) – Forecast and Market Analysis to 2023 in subject line and your contact details. GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluticasone Furoate (Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting betaagonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the latestage pipeline. GSK’s fluticasone furoate is marketed as Veramyst/Avamys/Allermyst in the US, EU, Japan, and Australia for the treatment of allergic rhinitis and is formulated as a nasal spray. Fluticasone furoate is also a component of Breo/Relvar, which is marketed in the EU and Japan for the treatment of COPD and asthma. This drug is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. When compared with fluticasone propionate, fluticasone furoate has 1.7-fold greater binding affinity for the glucocorticoid receptor. Complete report available at http://www.marketoptimizer.org/fluticasone-furoate-asthma-forecastand-market-analysis-to-2023.html . Scope Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Fluticasone Furoate including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Fluticasone Furoate for the top eight countries from 2013 to 2023. Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Reasons to Buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Asthma Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of Fluticasone Furoate performance

Obtain sales forecast for Fluticasone Furoate from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)
Inquire for discount @ http://www.marketoptimizer.org/contacts/discount?rname=10547 (Report price: Single user license- US$ 3495 ) Table of Contents 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Disease Overview 3.1 Etiology and Pathophysiology 3.1.1 Etiology 3.1.2 Pathophysiology 3.1.3 Prognosis 3.1.4 Quality of Life 3.2 Symptoms 4 Disease Management 4.1 Diagnosis and Treatment Overview 4.1.1 Diagnosis 4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
Buy a Copy of the Report @ http://www.marketoptimizer.org/contacts/purchase?rname=10547 . Table of Contents 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment
6 Unmet Need and Opportunity 6.1 Overview 6.2 Personalized Therapies to Control Severe Asthma 6.2.1 Unmet Need 6.2.2 Gap Analysis 6.2.3 Opportunity 6.3 Better Patient Compliance 6.3.1 Unmet Need 6.3.2 Gap Analysis 6.3.3 Opportunity 6.4 Lower Cost of Asthma Medications 6.4.1 Unmet Need 6.4.2 Gap Analysis 6.4.3 Opportunity 6.5 Proper Diagnosis of Asthma in Children Contact sales@marketoptimizer.org / Call +1 888 391 5441 for further information on “Fluticasone Furoate (Asthma) – Forecast and Market Analysis to 2023” report OR for any other market research and intelligence needs you may have for your business.